Kodiak Sciences saw a 71.2% stock increase on 26 March, reaching $38.95, fuelled by successful trial results for Zenkuda, a treatment for diabetic retinopathy. The stock’s recent strong performance highlights its potential despite trading below its all-time high.
Source :- mint – markets Read More
